dosing options and tailored therapy to fit individual patient needs1,2

Featuring similar technology to Glumetza®1,3,4*

INVOKAMET® XR2 pills, once daily

INVOKAMET®(canagliflozin/metformin HCl)1 pill, twice daily

INVOKAMET® XR is available in 4 strengths1

INVOKAMET® XR dosing chart

The dosage of INVOKAMET® XR and INVOKAMET® should be individualized on the basis of both effectiveness and tolerability while not exceeding the maximum recommended daily dose of canagliflozin (300 mg) and metformin (2000 mg).1,2

Individualize the starting dose of INVOKAMET® XR based on the effectiveness and tolerability of the patient's current regimen1

In patients currently not treated with either INVOKANA® (canagliflozin) or metformin:

  • Initiate therapy with 2 INVOKAMET® XR tablets, each tablet containing canagliflozin 50 mg and metformin 500 mg

In patients currently on metformin:

  • Switch to 2 INVOKAMET® XR tablets, where 2 tablets equal a starting dose of INVOKANA® 100 mg daily and the patient's current total daily dose (or nearest appropriate) of metformin

In patients currently on INVOKANA®:

  • Switch to 2 INVOKAMET® XR tablets, where 2 tablets equal the patient’s current total daily dose of INVOKANA® and a starting dose of metformin 1000 mg daily

In patients already treated with INVOKANA® and metformin:

  • Switch to 2 INVOKAMET® XR tablets containing the same total daily dose of INVOKANA® and the same, or nearest appropriate, total daily dose of metformin

Dosage and administration considerations1

  • Assess renal function before initiating INVOKAMET® XR and periodically thereafter
  • Take 2 INVOKAMET® XR tablets once daily with the morning meal
  • INVOKAMET® XR must be swallowed whole and never crushed, cut, or chewed
  • In patients who require additional glycemic control who are taking a total daily dose of INVOKANA® 100 mg, the INVOKAMET® XR dose can be increased to canagliflozin 300 mg once daily
  • The dose of metformin should be gradually escalated to reduce the gastrointestinal side effects due to metformin
  • Patients taking an evening dose of metformin XR should skip their last dose before starting INVOKAMET® XR the following morning
  • In patients with volume depletion not previously treated with INVOKANA®, correct this condition before initiating INVOKAMET® XR
  • Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin 2000 mg and canagliflozin 300 mg in patients with an eGFR ≥60 mL/min/1.73 m2
  • INVOKAMET® XR is contraindicated in patients with an eGFR <45 mL/min/1.73 m2
  • Limit the dose of INVOKAMET® XR to 2 tablets, each tablet containing canagliflozin 50 mg, in patients with moderate renal impairment with an eGFR of 45 to <60 mL/min/1.73 m2

For more information on dosing and administration for INVOKAMET® XR, please see full Prescribing Information and Medication Guide.

INVOKAMET® is available in 4 strengths2

INVOKAMET® dosing chart

The dosage of INVOKAMET® XR and INVOKAMET® should be individualized on the basis of both effectiveness and tolerability while not exceeding the maximum recommended daily dose of canagliflozin (300 mg) and metformin (2000 mg).1,2

Individualize the starting dose of INVOKAMET® based on the patient's current regimen2

In patients currently not treated with either INVOKANA® or metformin:

  • Initiate therapy with INVOKAMET® containing canagliflozin 50 mg and metformin 500 mg

In patients currently on metformin:

  • Switch to INVOKAMET® containing canagliflozin 50 mg and the same, or nearest appropriate, daily dose of metformin

In patients currently on INVOKANA®:

  • Switch to INVOKAMET® containing metformin 500 mg with the same daily dose of canagliflozin

In patients already treated with INVOKANA® and metformin:

  • Switch to INVOKAMET® containing the same daily dose of canagliflozin and the same, or nearest appropriate, daily dose of metformin

Dosage and administration considerations2

  • Assess renal function before initiating INVOKAMET® and periodically thereafter
  • Take 1 INVOKAMET® tablet twice daily with meals
  • In patients with volume depletion not previously treated with INVOKANA®, correct this condition before initiating INVOKAMET®
  • In patients tolerating canagliflozin 50 mg twice daily who have an eGFR ≥60 mL/min/1.73 m2 and require additional glycemic control, canagliflozin can be increased to 150 mg twice daily, with gradual metformin dose escalation to reduce the gastrointestinal side effects due to metformin
  • Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin 2000 mg and canagliflozin 300 mg in patients with an eGFR ≥60 mL/min/1.73 m2
  • INVOKAMET® is contraindicated in patients with an eGFR <45 mL/min/1.73 m2
  • Limit the dose of the canagliflozin component to 50 mg twice daily in patients with moderate renal impairment with an eGFR of 45 to <60 mL/min/1.73 m2

For more information on dosing and administration for INVOKAMET®, please see full Prescribing Information and Medication Guide.

*The metformin XR layer of INVOKAMET® XR doses contains Acuform® technology—the same XR delivery system as Glumetza® 500 mg.
Indicated trademarks are registered trademarks of their respective owners.

References: 1. INVOKAMET® XR [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. INVOKAMET® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. Depomed licenses Glumetza® data and Acuform® technology [press release]. Newark, CA: Depomed, Inc.; August 5, 2010. 4. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ.